← Back to headlines
GRI Bio to Present Phase 2a IPF Drug Data at ERS Congress
GRI Bio is scheduled to present late-breaking Phase 2a data for its IPF drug, GRI-0621, at the ERS Congress. The presentation will highlight lung function, anti-fibrotic biomarkers, and favorable tolerability in patients with Idiopathic Pulmonary Fibrosis.
24 Aug, 13:05 — 24 Aug, 13:05
Coverage Timeline
First report: taiwan-news · 24 Aug, 13:05|Full coverage: 2 · 8m|Window: 8m
Left-leaningCenterRight-leaning
